A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
Clinical trial NCT04459715 · TERMINATED
Trial details
- NCT number
- NCT04459715
- Sponsor
- EMD Serono Research & Development Institute, Inc.
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-07
- Primary completion
- 2024-09-18
- Enrollment
- 730
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.